Content validation of a daily patient-reported outcome measure for assessing symptoms in patients with Small Intestinal Bacterial Overgrowth.

"Declarations Conflict of interestGJ and AAD are employees of Bausch Pharma US, LLC. ND, OM, and JS are employed by ICON plc, of whom were commissioned by Bausch Pharma US, LLC to perform the study and develop this manuscript. Ethical approvalAll procedures performed in studies involving human patients were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The ethics bodies that approved the study at the four clinical sites were WCG IRB. Consent to participateInformed consent was obtained from all individual patients included in the study. Conflict of interest GJ and AAD are employees of Bausch Pharma US, LLC. ND, OM, and JS are employed by ICON plc, of whom were commissioned by Bausch Pharma US, LLC to perform the study and develop this manuscript."

"Funding This study was funded by Bausch Pharma US, LLC and conducted by ICON plc."